A Randomized Double-Blind, Sponsor-Open, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of TAK-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Subjects
Latest Information Update: 24 Apr 2023
At a glance
- Drugs Ondansetron (Primary) ; TAK 951 (Primary)
- Indications Postoperative nausea and vomiting
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda
- 21 Jul 2022 Status changed from active, no longer recruiting to completed.
- 28 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2022 Planned End Date changed from 31 Jan 2022 to 14 Dec 2022.